Agents that target specific molecules or cell signaling pathways, such as the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors, are standard now for treating advanced NSCLC [5, 8]. Here, EGFR is linked to non-small cell lung carcinoma.